stoxline Quote Chart Rank Option Currency Glossary
Lyra Therapeutics, Inc. (LYRA)
0.3101  0 (0.03%)    06-13 16:00
Open: 0.3053
High: 0.3149
Volume: 853,987
Pre. Close: 0.31
Low: 0.301
Market Cap: 19(M)
Technical analysis
2024-06-13 4:44:43 PM
Short term     
Mid term     
Targets 6-month :  0.43 1-year :  0.48
Resists First :  0.37 Second :  0.41
Pivot price 0.32
Supports First :  0.3 Second :  0.25
MAs MA(5) :  0.31 MA(20) :  0.33
MA(100) :  3.91 MA(250) :  3.82
MACD MACD :  -0.6 Signal :  -0.7
%K %D K(14,3) :  13.4 D(3) :  10.7
RSI RSI(14): 13.2
52-week High :  6.78 Low :  0.3
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ LYRA ] has closed above bottom band by 12.7%. Bollinger Bands are 98.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.32 - 0.32 0.32 - 0.32
Low: 0.3 - 0.3 0.3 - 0.3
Close: 0.31 - 0.31 0.31 - 0.31
Company Description

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Headline News

Fri, 14 Jun 2024
Biopharma Layoff Tracker 2024: Barinthus, Agilent, BMS and More Cut Staff - BioSpace

Tue, 21 May 2024
Lyra cuts 75% of staff, looks to sublease Waltham, Watertown facilities - The Business Journals

Tue, 21 May 2024
Lyra Therapeutics slashes workforce by 75% By -

Tue, 21 May 2024
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital - GlobeNewswire

Mon, 06 May 2024
LYRA Stock Quote Price and Forecast - CNN

Mon, 06 May 2024
Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 61 (M)
Held by Insiders 3.764e+007 (%)
Held by Institutions 0.6 (%)
Shares Short 334 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -7.161e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -4 %
Return on Assets (ttm) 421.8 %
Return on Equity (ttm) -38.1 %
Qtrly Rev. Growth 1.68e+006 %
Gross Profit (p.s.) 1490
Sales Per Share -4796.5
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -70 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0.1
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 603030
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android